-Live Mint An investigation found DCGI cleared drugs without conducting mandatory clinical trials After five rounds of consultations in six months, a committee tasked with making recommendations on cleaning up India’s drugs-approval process and ending the cosy relationship between doctors, pharmaceutical companies and government officials had no suggestions to offer by way of a crackdown. It has, instead, suggested setting up 20 sub-committees. The report submitted to the health ministry in November is...
More »SEARCH RESULT
No child left behind -Aarti Dhar
-The Hindu India’s polio triumph is a rare milestone in its uninspiring public health record. The story so far only strengthens the case for a vastly augmented routine immunisation programme to combat disease. India has been celebrating its near-victory over polio for the past two years, but it often hogs the headlines for unacceptably high mortality and morbidity due to other communicable diseases such as malaria, tuberculosis, dengue and filaria. The government now...
More »India Serves Up Costly Cocktail of Vaccines by Ranjit Devraj
Ignoring widespread concern over the safety, efficacy and cost of pentavalent vaccines, India’s central health ministry has, this month, approved inclusion of the prophylactic cocktail in the universal immunisation programme in seven of its provinces. Pentavalent vaccine doses, a cocktail of five antigens in a single shot, confers immunity against five paediatric diseases - diphtheria, pertussis, tetanus, hepatitis B and haemophilus influenza type b (Hib), with the last one considered particularly...
More »Delhi's irony: Urban Poverty-Srinand Jha
Each time 25 year old Salma takes her one year old son Zubair to the Batla Clinic (a private clinic in Delhi) for a shot of the DPT, the cost of transportation and the vaccine adds up to approximately Rs.500. When it is time for Zubair to take the next immunization dose, Salma may find that the expenses have entirely spiraled out of her reach. New vaccines and expensive brands of baby...
More »A historic move to make drugs affordable-G Ananthakrishnan
India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...
More »